雖然這篇empa-kidney鄉民發文沒有被收入到精華區:在empa-kidney這個話題中,我們另外找到其它相關的精選爆讚文章
[爆卦]empa-kidney是什麼?優點缺點精華區懶人包
你可能也想看看
搜尋相關網站
-
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#1EMPA-KIDNEY (The Study of Heart and Kidney Protection
EMPA -KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin) · Age ≥18 years or at "full age" as required by local regulation.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#2Welcome — EMPA-KIDNEY
EMPA -KIDNEY is a randomized double-blind placebo-controlled trial of empagliflozin versus matching placebo in 6,000 people with chronic kidney disease, with or ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#3a rationale for the EMPA-KIDNEY study - PubMed
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA- ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#4the study of heart and kidney protection with empagliflozin
EMPA -KIDNEY is a clinical trial testing whether taking a single pill of empagliflozin every day prevents worsening of kidney disease or deaths from heart ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#5Empagliflozin and Cardiovascular and Kidney Outcomes ...
Background and objectives In the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG Outcome), ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#6EMPA-Kidney | University of Utah Health
Since SGLT-2 inhibition with empagliflozin also causes glycosuria and acute haemodynamic changes in kidney function in people without diabetes, empaglifozin may ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#7Empagliflozin and Progression of Kidney Disease in ... - NEJM
Diabetes confers an increased risk of adverse cardiovascular and renal events. In the EMPA-REG OUTCOME trial, empagliflozin, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#8EMPA-KIDNEY (The Study of Heart and ... - Yale Medicine
Brief Summary:The primary aim of the study is to investigate the effect of empagliflozin on kidney disease progression or cardiovascular death versus ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#9EMPA-KIDNEY (The Study of Heart ... - Yale School of Medicine
Brief Summary:The primary aim of the study is to investigate the effect of empagliflozin on kidney disease progression or cardiovascular death versus ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#10the study of heart and kidney protection with empagliflozin
The EMPA-KIDNEY randomised trial is comparing empagliflozin 10 mg once daily ... chronic kidney disease (CKD) with or without diagnosed diabetes mellitus.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#11EMPA-KIDNEY (The Study of Heart and ... - Smart Patients
The primary aim of the study is to investigate the effect of empagliflozin on kidney disease progression or cardiovascular death versus placebo on top of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#12EMPA-KIDNEY (The Study of Heart and Kidney ... - CenterWatch
Clinical trial for chronic kidney disease (ckd) | chronic renal insufficiency | Chronic renal failure | chronic kidney disease , EMPA-KIDNEY (The Study of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#13Cardio/Kidney Composite End Points: A Post Hoc Analysis of ...
This post hoc analysis of the EMPA‐REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#14EMPA-KIDNEY: Introduction to the trial - YouTube
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#15The EMPA-KIDNEY Study - Health Research Authority
EMPA -KIDNEY is a clinical trial aiming to test whether taking a medication called empagliflozin lowers the risk of worsening kidney disease or heart disease ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#16A New Era in Managing Diabetic Kidney Disease Starts Now
13 The Study of Heart and Kidney Protection With Empagliflozin (EMPA-KIDNEY)14 is recruiting patients whose eGFR can be as low as 20 mL/min/1.73 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#17DCRI, University of Oxford to collaborate on chronic kidney ...
April 18, 2018 – EMPA-KIDNEY will study the effects of empagliflozin in CKD patients with and without diabetes.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#18EMPA-KIDNEY study; the study of heart and kidney protection with ...
EMPA -KIDNEY study; the study of heart and kidney protection with Empagliflozin in patients with CKD with or without T2D. Document ID: SC-SA-00211.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#19Empagliflozin cuts risk of CV, Kidney events regardless of ...
This covers the ongoing EMPA-KIDNEY trial, which is investigating the drug's effect on the progression of kidney disease and occurrence of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#20A rationale for the EMPA-KIDNEY study - ResearchGate
sodium-glucose co-transporter-2 inhibition in people. with chronic kidney disease: a rationale for the. EMPA-KIDNEY study.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#21US FDA grants Fast Track designation ... - Boehringer Ingelheim
EMPA -KIDNEY is a multinational randomized, double-blind, placebo-controlled clinical trial. It is designed to evaluate the effect of Jardiance ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#22EMPA-KIDNEY | Cochrane Library
EMPA -KIDNEY. JPRN‐JapicCTI‐184172. http://www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-JapicCTI-184172, 2018 | added to CENTRAL: 31 July 2019 | 2019 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#23248-OR: Empagliflozin and Cardiorenal Outcomes in Patients ...
This result suggests that absence of overt proteinuria may not alter the cardiorenal treatment response to EMPA. The ongoing EMPA-KIDNEY study investigates ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#24FDA fast tracks empagliflozin for treatment of chronic kidney ...
The fast track designation is based on the ongoing EMPA-Kidney clinical study, which is evaluating the effect of empagliflozin (Jardiance) on ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#25Dedicated kidney disease‐focused outcome trials with sodium ...
1.5 Ongoing trials in CKD: DAPA-CKD and EMPA-KIDNEY. Two large-scale RCTs are examining the effects of SGLT2 inhibitors on kidney disease- ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#26Association of SGLT2 Inhibitors With Cardiovascular and ...
In EMPA-REG OUTCOME and the CANVAS program trials, analysis of the kidney composite outcome was prespecified as exploratory.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#27updated results from the ABCD nationwide empagliflozin audit
The EMPA-KIDNEY trial is currently underway and is assessing whether there are ben- efits of empagliflozin in improving renal outcomes in people.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#28Empagliflozin Improved Outcomes for Patients With Heart ...
Empagliflozin improved cardiovascular outcomes and slowed kidney function decline across the full range of kidney function down to an eGFR of 20 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#29Die Studie zur Herz- und Nierenprotektion mit Empagliflozin - DGfN
EMPA -Kidney - Die Studie zur Herz- und Nierenprotektion mit Empagliflozin ... Multizentrische, internationale, randomisierte, doppelblinde Placebo-kontrollierte ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#30Characterization and implications of the initial - Kidney ...
estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#31DE - EU Clinical Trials Register
EMPA -KIDNEY (The study of heart and kidney protection with empagliflozin) ... Protocol: EMPA-KIDNEY Body composition measurement substudy ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#32Study Details - Research for Me
EMPA -KIDNEY. Scientists are searching for new treatments to reduce the risk of kidney and heart problems in people with kidney disease.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#33New Jardiance® findings showed improved cardio-renal ...
This designation covers the ongoing EMPA-KIDNEY trial, which is investigating the effect of Jardiance on the progression of kidney disease and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#34An Analysis From the EMPA-REG OUTCOME Trial - American ...
The prevalence of diabetic kidney disease among US adults with diabetes has remained steady at ∼25% over the last 20 years despite increased ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#35Empagliflozin Fast-Tracked for Chronic Kidney Disease ...
The designation is supported by data from the ongoing double-blind, placebo-controlled phase 3 EMPA-KIDNEY trial, which is comparing the effects ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#36The Clinical Landscape of Managing Type 2 - 內科醫學會
Sodium-Glucose Cotransporter-2 Inhibitors and Diabetic Kidney Disease. 323. The incidence of diabetic ... proportions of stage 3 CKD patients with empa-.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#37Kidney Week - American Society of Nephrology
In DM mice (BTBR) without EMPA, blood glucose concentration was higher than control, and lower in diabetic mice treated with EMPA compared to DM. Urine volume ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#38Empagliflozin decreases risk of kidney function decline in type ...
... risk of kidney function decline in type 2 diabetes: slope analyses in patients with / without heart failure at baseline from the EMPA-REG OUTCOME trial.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#39EMPA-Kidney Archives - Medical Conferences
Faiez Zannad, University of Lorraine, France; Trial: EMPEROR-Reduced; DAPA=HF; DAPA-CKD; EMPA-Kideney; Conference: HFA 2021.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#40SGLT2i , Diabetes and CKD care How do we change practice
CREDENCE, EMPA-KIDNEY. ‒ NIH: Kidney Precision Medicine Project; ... CKD, chronic kidney disease; SGLT2, sodium–glucose co-transporter 2.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#41Renoprotection with SGLT2 inhibitors in type 2 diabetes over ...
In many of them, chronic kidney disease (CKD) progresses over time, ... Table 1 Baseline renal status in EMPA-REG OUTCOME, CANVAS program, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#42Canagliflozin and Renal Outcomes in Type 2 Diabetes and ...
The Empagliflozin Cardiovascular Outcomes and Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) 7 trial and the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#43DIABETIC KIDNEY DISEASE
De initive clinical trials (DAPA CKD and EMPA KIDNEY) are underway to study the use of SGLT2 inhibitors in CKD patients with or without type 2 diabetes.25, 41, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#44Clinical Trial on Chronic Kidney Disease: Empagliflozin ...
EMPA -KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin). A Multicentre International Randomized Parallel Group Double-blind ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#45EMPA-REG Renal results. - NephJC
Putting the mellitus back into diabetes. Is inducing glycusuria the key to diabetic nephropathy? EMPA-REG renal outcomes.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#46Chronic kidney disease drug empagliflozin fast-tracked by FDA.
The aim is to assess the drug's effect on the progression of kidney disease and cardiovascular death. EMPA-KIDNEY comes from exploratory data of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#47BI, Lilly announces results of new post-hoc analysis of data ...
... of cardiovascular and kidney outcomes was consistent between people in the EMPA-REG OUTCOME trial who had chronic kidney disease without ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#48a rationale for the EMPA-KIDNEY study | Semantic Scholar
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#49Swapnil Hiremath, MD в Twitter: "@kidney_boy Umm EMPA ...
EMPA -kidney including non-albuminuric CKD, there is still equipoise there, I think!
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#50|NIPH Clinical Trials Search - 国立保健医療科学院
EMPA -KIDNEY · Basic Information · Outcome(s) · Key inclusion & exclusion criteria · Related Information · Contact ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#51FDA approval of dapagliflozin for chronic kidney disease - The ...
The Study of Heart and Kidney Protection With Empagliflozin (EMPA-KIDNEY; NCT03594110) enrolled CKD patients, including those without ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#52Fast Track designation granted to chronic kidney disease ...
The ongoing EMPA-KIDNEY clinical study is evaluating the effect of Jardiance on the progression of kidney disease and the occurrence of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#53FDA fast-tracks Lilly/Boehringer's Jardiance in chronic kidney ...
The FDA has awarded the fast-track designation for the CKD indication based on that result, as well as the promise of an ongoing trial – EMPA- ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#54New post-hoc analysis shows consistent cardiorenal risk ...
Findings from a post-hoc analysis of the EMPA-REG OUTCOME ® trial in adults with type 2 diabetes and chronic kidney disease without overt ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#55Do Renal Benefits of Empagliflozin Vary By Glycemic Control ...
In type 2 diabetes, empagliflozin (EMPA) likely has beneficial renal effects regardless of patients' level of glycemic control prior to and during therapy, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#56sat-305 effects of empagliflozin vs placebo on cardiorenal ...
... PROTEINURIC DIABETIC KIDNEY DISEASE: INSIGHTS FROM EMPA-REG OUTCOME ... of people from the EMPA-REG OUTCOME trial who met the key renal ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#57EMPA-KIDNEY (The Study of Heart and Kidney Protection ...
The primary aim of the study is to investigate the effect of empagliflozin on kidney disease progression or cardiovascular death versus ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#58Boehringer Ingelheim and Lilly Announce an ... - elEconomista.es
EMPA -KIDNEY will investigate the effects of empagliflozin on the progression of kidney disease and the occurrence of cardiovascular death, in people with ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#59Boehringer Ingelheim and Lilly announce an ... - TCTMD
EMPA -KIDNEY will include approximately 5,000 adults with established chronic kidney disease, with and without diabetes.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#60Bayer's big kidney disease readout approaches | Evaluate
Bayer has invested heavily in finerenone in kidney disease, ... Astrazeneca's Dapa-CKD study of Farxiga and Lilly's Empa-Kidney trial of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#61AstraZeneca's Farxiga backs up kidney disease trial stop with ...
The FDA will base its review on results from the ongoing Empa-Kidney outcomes trial, which is studying Jardiance's effect on the progression ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#62US FDA Grants Fast Track Designation to Jardiance® for the ...
“We recognize the close link between the health of the heart, kidneys and metabolic system, ... About Chronic Kidney Disease ... About EMPA-KIDNEY.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#63New analysis shows cardiorenal risk reductions of Jardiance ...
To that end, we have initiated an outcomes trial, EMPA-KIDNEY, to investigate the effects of empagliflozin on cardiovascular death and the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#64New CREDENCE Data Support SGLT2 Inhibitor Use in ...
... 4000 participants with type 2 diabetes and chronic kidney disease. ... of Heart and Kidney Protection With Empagliflozin (EMPA-Kidney), ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#65Kidney protection and SGLT2i: What do we know? - PACE-CME
Which statement is true about renal outcomes of recent SGLT2i trials? ... had renal benefit with empagliflozin; C. Use of SGLT2i in EMPA-REG ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#66更新履歴 / update history information - 臨床試験情報詳細画面 ...
EMPA -KIDNEY試験は,エンパグリフロジン10 mgが,糖尿病合併の有無にかかわらず慢性腎臓病患者の腎疾患進行又は心血管死のリスクを減少させるか否か,その治療効果が副作用 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#67Studie zu Empagliflozin - EMPA-KIDNEY: auf Herz und Nieren ...
Die EMPA-KIDNEY-Studie soll nun zeigen, ob der Herz- und Nierenschutz des SGLT-2-Hemmers auch bei Patienten ohne Diabetes vorliegt.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#68Dedicated kidney disease-focused outcome trials with sodium ...
... outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY. Authors.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#69Randomised trials in cardiovascular and metabolic disease - GtR
The EMPA-KIDNEY trial will recruit at least 5000 participants with chronic kidney disease (at least a third with and a third without diabetes) and compare ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#70CREDENCE- Canagliflozin (INVOKANA) & Renal Outcomes ...
Canagliflozin and Renal Events in Diabetes with Established Nephropathy ... The DAPA-CKD (estimated completion Nov 2020) and EMPA-KIDNEY ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#71中国医学科学院阜外医院EMPA-KIDNEY研究样本运输成交公告
二、项目名称:中国医学科学院阜外医院EMPA-KIDNEY研究样本运输. 三、中标(成交)信息. 供应商名称:中集冷云(北京)供应链管理有限公司.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#72BI, Lilly To Test Diabetes Drug Jardiance in Kidney Disease
The trial, EMPA-KIDNEY, will be independently conducted, analyzed, and reported by the Medical Research Council Population Health Research ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#73mediators of the empagliflozin treatment effect on kidney ...
MEDIATORS OF THE EMPAGLIFLOZIN TREATMENT EFFECT ON KIDNEY OUTCOMES IN THE EMPA-REG OUTCOME TRIAL. M JARDINE 1, C WANNER 2, M NANGAKU 3, B KRAUS 4,5,6, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#74EMPA-REG OUTCOME: The Nephrologist's Point of View
Diabetic kidney disease develops gradually over ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#75What have we learned from DAPA-HF? | BCS - British ...
CKD: DAPA-CKD (Dapaglifozin, NCT03036150) and EMPA-Kidney (Empaglifozin, NCT03594110). Type 2 diabetes with multiple risk factors and moderate renal ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#76Canagliflozin reduced kidney failure and CV events at 2.6 ...
Canagliflozin reduced risk for kidney failure and CV events. These findings are consistent with the CANVAS program and EMPA-REG trials, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#77Commentary on Cardiorenal Protection With the Newer ...
The ongoing EMPA-KIDNEY (empagliflozin versus placebo) and FLOW (semaglutide versus placebo) trials utilize similar inclusion criteria (eGFR ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#78Empa-Kidney 2nd Malaysia Investigator and Research Nurse ...
Empa -Kidney 2nd Malaysia Investigator and Research Nurse Initiation Meeting 4th-5th April 2019 JW Marriot Hotel, KL PI: Dr Muhammad Iqbal Abdul Hafidz...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#79recovery-intervention-sheet-empagliflozin-v1-0.pdf
Is empagliflozin contraindicated in renal impairment? ... function in large trials (such as DAPA-CKD and EMPA-KIDNEY) and treatment is.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#80Neue Diabetesstudien - Nephrologisches Seminar Heidelberg -
CREDENCE (15.4.2019) - DAPA CKD (2020) - EMPA-KIDNEY (2022). Limitationen: In den Cardiovascular Outcome Studien (CVOTS) waren die.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#81Die EMPA-KIDNEY Studie - medicom.cc
Die EMPA-KIDNEY Studie: ... Die Ergebnisse der EMPA-REG-OUTCOME Studie (Wanner C; N Engl J Med 2016; 375:323), des CANVAS-R-Programms (Neal B; ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#82Würzburg rekrutiert ersten Patienten für EMPA-Kidney Studie
connexi Ausgabe 2-2019EMPA-KIDNEY StudieEmpagliflozinSGLT2-InhibitorEMPA-REG-OUTCOME-StudieChristoph WannerUniversity OxfordUniversity ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#83EMPA-REG OUTCOME (ESRD) - Wiki Journal Club
"Empagliflozin and progression of kidney disease in type 2 diabetes". The New England Journal of Medicine. 2016. 375(4):323-334. PubMed ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#84US FDA accepts supplemental New Drug Application for ...
This designation covers the ongoing EMPA-KIDNEY trial, the results of which are expected in 2022. Jardiance is not indicated for the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#85Studies Results - Be Involved | Wake Forest Baptist Health
EMPA -KIDNEY: Study of the drug EMPAgliflozin to prevent cardiac issues in ... of kidney disease or deaths from heart disease among people who have kidney ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#86Cost-Effectiveness of Empagliflozin in Patients With Diabetic ...
Benefits of sodium-glucose co-transporter 2 inhibitors on kidney ... 12, 13 The ongoing EMPA-KIDNEY trial will provide further evidence in ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#87Effects of dapagliflozin on major adverse kidney and ...
Running head: Dapagliflozin in diabetic and non-diabetic chronic kidney disease ... regardless of diabetes status.21 The ongoing EMPA-KIDNEY study (Study of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#88Kidney Clinic - CREDENCE: new hope in diabetes
Trials are now under way with the two other SGLT2 inhibitors: Dapa-CKD with dapagliflozin and EMPA-Kidney with empagliflozin.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#89Würzburg randomisiert 100. Patienten für Studie zum Herz
nationale klinische EMPA-KIDNEY Studie randomisiert wurde, also auf eine Kontroll- oder Vergleichsgruppe verteilt wurde.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#90EMPA-KIDNEY - Studie zur Schutz von Herz und Nieren durch ...
EMPA -KIDNEY - Studie zur Schutz von Herz und Nieren durch Empagliflozin · Neue Besuchsregeln ab dem 30. August 2021 · 3G-Regelung auch im Klinikum Braunschweig.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#91Jennifer Brigitte Green, MD
Endocrinology and Metabolism Training Program · EMPA-KIDNEY Trial · Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#92자디앙®의 효과 평가를 위한 연구 협력 발표 - eMD Medical News
옥스퍼드대, 만성 신장 질환 환자 대상 심장 및 신장질환에 대한 자디앙®의 효과 평가. EMPA-KIDNEY 연구, 광범위한 유형의 환자 및 임상 조건에서 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#93Back to the Future 2020−2021 - Kidney News Online
when it was featured in Canagliflozin and Renal Events ... We now eagerly await the results of the EMPA-KIDNEY.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#94Empagliflozin and Progression of Kidney Disease in Type 2 ...
EMPA -REG OUTCOME ha più recentemente valutato gli effetti di empagliflozin su outcome renali pre-specificati quali: 1. incidenza o progressione di DKD (cioè ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#95ERBP guideline on management of patients with diabetes and...
28 published the results of the EMPA-REG Renal study, with data from patients in the same clinical trial. Empagliflozin delayed the progression of kidney damage ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#96New guidance on sodium glucose co-transporter 2 inhibitors ...
On 18 October 2021, the UK Kidney Association (UKKA) published ... CKD when the EMPA-KIDNEY trial reports in 2022 (Herrington et al, 2018).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#97Jennifer Green - Google Scholar
... cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?>
empa-kidney 在 コバにゃんチャンネル Youtube 的精選貼文
empa-kidney 在 大象中醫 Youtube 的最佳解答
empa-kidney 在 大象中醫 Youtube 的最佳貼文